Advertisement

Cytotoxic Chemotherapy for Diffuse Gliomas

  • Ivo W. Tremont-Lukats
  • Mark R. Gilbert
Part of the M. D. Anderson Cancer Care Series book series (MDCCS)

Keywords

Clin Oncol Malignant Glioma Radiat Oncol Biol Phys Radiation Therapy Oncology Group Anaplastic Glioma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barrie M, Couprie C, Dufour H, et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol 2005;16:1177–1184.PubMedCrossRefGoogle Scholar
  2. Beauchesne P, Soler C, Boniol M, Schmitt T. Response to a phase II study of concomitant-to-sequential use of etoposide and radiation therapy in newly diagnosed malignant gliomas. Am J Clin Oncol 2003;26:e22–e27.PubMedCrossRefGoogle Scholar
  3. Brada M, Ashley S, Dowe A, et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol 2005;16:942–949.PubMedCrossRefGoogle Scholar
  4. Brandes AA, Rigon A, Zampieri P, et al. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. Cancer 1998;82:355–361.PubMedCrossRefGoogle Scholar
  5. Brandes AA, Rigon A, Zampieri P, et al. Early chemotherapy and concurrent radio-chemotherapy in high grade glioma. J Neurooncol 1996;30:247–255.PubMedCrossRefGoogle Scholar
  6. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345:1008–1012.CrossRefGoogle Scholar
  7. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy alone for pure and mixed anaplastic oligodendrogliomas: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707–2014.PubMedCrossRefGoogle Scholar
  8. Del Rowe J, Scott C, Werner-Wasik M, et al. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 2000;18:1254–1259.PubMedGoogle Scholar
  9. Diaz R, Jorda MV, Reynes G, et al. Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: a single-center experience. Anticancer Drugs 2005;16:323–329.PubMedCrossRefGoogle Scholar
  10. Fernandez-Hidalgo OA, Vanaclocha V, Vieitez JM, et al. High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients. Bone Marrow Transplant 1996;18:143–149.PubMedGoogle Scholar
  11. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585–2597.PubMedCrossRefGoogle Scholar
  12. Fisher B, Won M, Macdonald D, Johnson DW, Roa W. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 2002;53:980–986.PubMedGoogle Scholar
  13. Fountzilas G, Karavelis A, Makrantonakis P, et al. Concurrent radiation and intracarotid cisplatin infusion in malignant gliomas: a feasibility study. Am J Clin Oncol 1997;20:138–142.PubMedCrossRefGoogle Scholar
  14. Frenay M, Lebrun C, Lonjon M, Bondiau PY, Chatel M. Up-front chemotherapy with fotemustine (F)/cisplatin (CDDP)/etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. Eur J Cancer 2000;36:1026–1031.PubMedCrossRefGoogle Scholar
  15. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999;17:1516–1525.PubMedGoogle Scholar
  16. Gilbert MR, Friedman HS, Kuttesch JF, et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncology 2002;4:261–267.PubMedCrossRefGoogle Scholar
  17. Glantz MJ, Choy H, Kearns CM, et al. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 1996;14:600–609.PubMedGoogle Scholar
  18. Grossman S. Management of glioblastoma multiforme. In: Perry MC, ed. ASCO 2005 Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2006;180–186.Google Scholar
  19. Grossman SA, Wharam M, Sheidler V, et al. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 1997;15:2596–2603.PubMedGoogle Scholar
  20. Grossman SA, O'Neill A, Grunnet M, et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 2003;21:1485–1491.PubMedCrossRefGoogle Scholar
  21. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002;20:1383–1388.PubMedCrossRefGoogle Scholar
  22. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003.PubMedCrossRefGoogle Scholar
  23. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839–845.PubMedGoogle Scholar
  24. Jaeckle KA, Hess KR, Yung WK, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2003;21: 2305–2311.PubMedCrossRefGoogle Scholar
  25. Kleinberg L, Grossman SA, Piantadosi S, Zeltzman M, Wharam M. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. Int J Radiat Oncol Biol Phys 1999;44:535–543.PubMedCrossRefGoogle Scholar
  26. Lang FF, Gilbert MR, Puduvalli VK, et al. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro-Oncology 2002;4:268–277.PubMedCrossRefGoogle Scholar
  27. Larner JM, Phillips CD, Dion JE, Jensen ME, Newman SA, Jane JA. A phase 1–2 trial of superselective carboplatin, low-dose infusional 5-fluorouracil and concurrent radiation for high-grade gliomas. Am J Clin Oncol 1995;18:1–7.PubMedCrossRefGoogle Scholar
  28. Levin VA. The place of hydroxyurea in the treatment of primary brain tumors. Semin Oncol 1992;19:34–39.PubMedGoogle Scholar
  29. Levin VA, Hess KR, Choucair A, et al. Phase III randomized study of postradiotherapy chemotherapy with combination α-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003;9:981–990.PubMedGoogle Scholar
  30. Levin VA, Maor MH, Thall PF, et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1995;33: 357–364.PubMedGoogle Scholar
  31. Levin VA, Silver P, Hannigan J, et al. Superiority of post-radiotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990;18:321–324.PubMedGoogle Scholar
  32. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8: 1277–1280.PubMedGoogle Scholar
  33. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001;19:509–518.Google Scholar
  34. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012–2024.PubMedCrossRefGoogle Scholar
  35. Perry JR, DeAngelis LM, Schold SC Jr, et al. Challenges in the design and conduct of phase III brain tumor therapy trials. Neurology 1997;49:912–917.PubMedGoogle Scholar
  36. Prados MD, Scott C, Curran WJ Jr, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 1999;17:3389–3395.PubMedGoogle Scholar
  37. Rajkumar SV, Buckner JC, Schomberg PJ, et al. Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. Int J Radiat Oncol Biol Phys 1998;42:969–975.PubMedGoogle Scholar
  38. Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005;23:9359–9368.PubMedCrossRefGoogle Scholar
  39. Schuck A, Muller SB, Kohler A, et al. Combined radiochemotherapy with paclitaxel in the treatment of malignant glioma. Strahlenther Onkol 2002;178:486–490.PubMedCrossRefGoogle Scholar
  40. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011–1018.PubMedCrossRefGoogle Scholar
  41. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375–1382.PubMedCrossRefGoogle Scholar
  42. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–996.PubMedCrossRefGoogle Scholar
  43. van den Bent MJ, Chinot O, Boogerd W, et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 2003a:14:599–602.PubMedCrossRefGoogle Scholar
  44. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003b:21:2525–2528.PubMedCrossRefGoogle Scholar
  45. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323–1329.PubMedGoogle Scholar
  46. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5:79–88.PubMedCrossRefGoogle Scholar
  47. Wick W, Hermisson M, Kortmann RD, et al. Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study. J Neurooncol 2002;59:151–155.PubMedCrossRefGoogle Scholar
  48. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17: 2572–2578.PubMedGoogle Scholar
  49. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762–2771.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Ivo W. Tremont-Lukats
  • Mark R. Gilbert
    • 1
  1. 1.Department of NeurosurgeryThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations